Quelling of Excitotoxicity in Acute Stroke With Ketamine

Part of paid clinical trials in Wynnewood, Pennsylvania.

Sponsor
Lower Merion Neurology Research Foundation
Study ID
NCT03223220
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ketamine — DRUG
    IV infusion
  • Normal Saline — OTHER
    IV infusion
  • Midazolam injection — DRUG
    Injection

Study Details

The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.

Key Dates

Start date
Jul 1, 2024
Status verified
Dec 2023
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Study Drug
    Will receive Ketamine infusion, and Midazolam (Versed).
  • Placebo Comparator: Placebo
    Will receive Normal saline infusion and Midazolam (Versed).

Primary Outcome Measure

Change in weighted modified Rankin scale score between day 1 and 90 will be assessed. [ Time Frame: On day 1 and at 90 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Lankenau Medical CenterWynnewoodPennsylvania19096
Sudhir Aggarwal, MD, PhD
[email protected]
484-413-2572

Find similar trials in Wynnewood, PA

By condition
Stroke
By specialty
NeurologyBrain disorders
By research site
Lankenau Medical Center· Wynnewood, PA

Related Studies